BRAF and melanoma: To the best of our knowledge, this is the first evidence demonstrating that NK ligand expression is modulated by the BRAF inhibitor PLX4032, and that expression can be restored/upregulated by inhibition of HO-1 in melanoma cells adapted to normoxia or hypoxia.